Group 9 metal-based inhibitors of β-amyloid (1-40) fibrillation as potential therapeutic agents for Alzheimer's disease

Bradley Yat Wah Man, Ho Man Chan, Chung Hang Leung, Daniel Shiu Hin Chan, Li Ping Bai, Zhi Hong JIANG, Hung Wing LI, Edmond Dik Lung MA*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

102 Citations (Scopus)

Abstract

We report here the first application of Group 9 metal complexes (i.e. iridium(III) and rhodium(III)) as inhibitors of amyloid fibrillogenesis and as luminescent probes for Aβ1-40 peptide. These complexes contained aromatic co-ligands to interact with the hydrophobic residues around the N-terminal domain of the Aβ1-40 peptide, as well as solvato co-ligands to allow coordinative bond formation with histidine residues. We demonstrate that these complexes could inhibit Aβ1-40 peptide aggregation in vitro, with potency superior to previous metal-based inhibitors reported. Furthermore, we have demonstrated the first example of luminescent detection of Aβ1-40 peptides by transition metal complexes.

Original languageEnglish
Pages (from-to)917-921
Number of pages5
JournalChemical Science
Volume2
Issue number5
DOIs
Publication statusPublished - 2011

Scopus Subject Areas

  • Chemistry(all)

Fingerprint

Dive into the research topics of 'Group 9 metal-based inhibitors of β-amyloid (1-40) fibrillation as potential therapeutic agents for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this